Significant research has demonstrated the ability of growth factors and other therapeutic proteins to induce the regeneration of tissue. However, considerable limitations have minimized the extent to which such proteins are able to successfully treat orthopedic diseases. Specifically, therapeutic proteins are expensive to cultivate and destabilize within minutes of their application, quickly losing their regenerative capabilities.
TissueGene has developed a novel method for overcoming the challenges associated with therapeutic proteins by harnessing their regenerative capabilities in a sustainable and cost-effective manner. The company has leveraged the emerging science of cell-mediated gene therapy to accomplish this goal, whereby a selected cell type is genetically modified to express a specific therapeutic protein and subsequently injected directly into the damaged tissue. This provides the damaged areas prolonged exposure to the therapeutic protein and effectively addresses the limitations typically associated with these proteins.